Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial

Authors:

Abstract
No abstract available
Funding Information
  • Fudan University (2020ZSLC06)
  • Zhongshan Hospital

This publication has 33 references indexed in Scilit: